159. Xeroderma pigmentosum
5 clinical trials,   13 drugs   (DrugBank: 4 drugs),   4 drug target genes,   13 drug target pathways
Searched query = "Xeroderma pigmentosum", "XP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04500548 (ClinicalTrials.gov) | February 26, 2021 | 4/8/2020 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | 3CI Study: Childhood Cancer Combination Immunotherapy. Phase Ib and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent, and Young Adult (CAYA) Patients With Relapsed/Refractory Hypermutant Cancers | Constitutional Mismatch Repair Deficiency Syndrome;Hematopoietic and Lymphoid Cell Neoplasm;Lynch Syndrome;Recurrent Lymphoma;Recurrent Malignant Solid Neoplasm;Recurrent Neuroblastoma;Recurrent Primary Central Nervous System Neoplasm;Refractory Lymphoma;Refractory Malignant Solid Neoplasm;Refractory Neuroblastoma;Refractory Primary Central Nervous System Neoplasm;Xeroderma Pigmentosum | Procedure: Biospecimen Collection;Biological: Ipilimumab;Biological: Nivolumab | National Cancer Institute (NCI) | NULL | Not yet recruiting | 12 Months | 25 Years | All | 40 | Phase 1 | NULL |